Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.

Last updated on 22-8-2019 by Anonymous (non vérifié)

Peer reviewed scientific article




The modified vaccinia virus Ankara (MVA) strain, which has been developed as a vaccine against smallpox, is since the nineties widely tested in clinical trials as recombinant vector for vaccination or gene therapy applications. Although MVA is renowned for its safety, several biosafety aspects need to be considered when performing the risk assessment of a recombinant MVA (rMVA). This paper presents the biosafety issues and the main lessons learned from the evaluation of the clinical trials with rMVA performed in Belgium. Factors such as the specific characteristics of the rMVA, the inserted…

Associated health topics:

QR code

QR code for this page URL